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Coronary angiography falls short in accurately delineat-ing the anatomy of epicardial vessels because it provides 
only a 2-dimensional visualization of the lumen.1 Moreover, 
angiographic lesion assessment is impeded in cases of diffuse 
disease of reference vessels, lesion foreshortening, and eccen-
tricity, and the overlap of several arterial branches, as well. 
Conversely, intravascular ultrasound—a sound wave–based 
technology—provides superior spatial resolution of 80 to 150 
μm and extends diagnostic information, enabling more pre-
cise assessment of lumen and vessel wall dimensions includ-
ing atheroma burden and vessel remodeling.
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Intravascular ultrasound (IVUS) has been proposed for the 
assessment of lesion severity in cases of intermediate left main 
and non–left main lesions. In addition, IVUS has been used to 
guide percutaneous coronary interventions (PCI) by informing 
the operator of reference vessel dimensions, lesion length, and 
extent of calcification to plan the procedure. Finally, IVUS 
has been implemented to optimize stent deployment, and cri-
teria have been developed such as the Multicenter Ultrasound 
Guided Stent Implantation (MUSIC)2 and Angiography ver-
sus IVUS Optimization (AVIO)3 criteria to this effect.
During the bare metal stent era, IVUS guidance was 
reported to reduce the risk of restenosis and repeat revascu-
larization.4 In contrast, the use of IVUS after drug-eluting 
stent (DES) implantation failed to improve clinical efficacy 
with IVUS guidance despite larger stent dimensions at the 
end of the procedure. Notwithstanding, some studies sug-
gested a lower risk of stent thrombosis with IVUS-guided 
DES implantation owing to the detection of mechanical fac-
tors associated with stent thrombosis, including edge dissec-
tions, stent malapposition, and stent underexpansion.5 More 
recently, the propensity score–matched comparison of IVUS 
guided with angiography-guided PCI of unprotected left main 
lesions (MAIN-COMPARE)6 reported lower mortality, with 
IVUS guidance potentially related to a lower risk of sudden 
death and stent thrombosis.
Current American College of Cardiology Foundation/
American Heart Associate PCI guidelines7 consider IVUS as 
a potential diagnostic tool for the assessment of intermediate 
left main lesions, cardiac allograft vasculopathy (IIa, B), and 
the evaluation of the mechanism of in-stent restenosis (IIa, C). 
Furthermore, the guidelines give room to support coronary 
stent implantation particularly in cases of stent implantation 
in the left main coronary artery (IIb, B). However, the uptake 
of IVUS to guide PCI has been modest (<5% of procedures) 
at best since its introduction in the early 1990s.8 Reasons for 
this restraint are the added complexity and prolongation of 
the procedure and a paucity of solid scientific data in support 
of IVUS-guided PCI. Previous randomized studies2,3,9,10 were 
largely underpowered and enrolled low-risk patients in whom 
the potential benefit of intravascular imaging was predictably 
low. Several small observational studies reported conflicting 
results, and a recent systematic review summarizing these 
studies suggested a benefit of IVUS-guided PCI in terms of 
death and stent thrombosis without differences in myocardial 
infarction and target lesion revascularization.11
Against this background, Witzenbichler and colleagues12 
provide new evidence of a prespecified substudy of the Platelet 
Reactivity and Clinical Outcomes After Coronary Artery 
Implantation of Drug-eluting Stents (ADAPT) DES regis-
try comparing clinical outcomes between IVUS-guided and 
 angiography-guided PCI. In propensity-adjusted multivariable 
analysis, IVUS guidance was strongly associated with reduced 
rates of definite/probable stent thrombosis (adjusted hazard 
ratio, 0.40; 95% confidence interval, 0.21–0.73; P=0.003), myo-
cardial infarction (adjusted hazard ratio, 0.66; 95% confidence 
interval, 0.49–0.88; P=0.004), and major adverse coronary 
events (adjusted hazard ratio, 0.70; 95% confidence interval, 
0.55–0.88; P=0.003) at 1 year with the greatest benefit emerg-
ing among patients with acute coronary syndrome and complex 
lesions (eg, left main, bifurcation, multivessel PCI). The study 
has several notable strengths. First, ADAPT DES is the largest 
prospective IVUS study performed to date with 3349 patients 
undergoing IVUS-guided PCI and 5234 patients undergoing 
angiography-guided PCI. Second, the study was performed in 
the setting of an all-comers patient population with a consider-
able proportion of patients with high-risk clinical characteristics 
including diabetes mellitus (31%), acute coronary syndrome 
(55%), ST-elevation myocardial infarction (12%), and lesion 
subsets (14% bifurcation lesions, 4% left main, 25% 3-vessel 
disease). Third, the investigators used propensity-adjusted mul-
tivariable analyses in an attempt to minimize the risk of bias. 
Fourth, prespecified and clinical events committee–adjudicated 
clinical end points were implemented as for the primary end 
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point, and, fifth, the investigators performed paired IVUS 
before and after the procedure in 60% of cases.
The following shortcomings deserve comment. The most 
prominent limitation of this observational study is the lack of 
randomization resulting in important differences in patient and 
lesion characteristics. IVUS patients were younger, had less pre-
vious coronary artery bypass graft surgery and 3-vessel disease, 
had a more extended duration of dual-antiplatelet therapy, and 
received new-generation DES more frequently. These differ-
ences indicate that IVUS assignment was not free from bias, 
and, despite using propensity-adjusted multivariable analyses, 
residual confounding factors cannot be excluded beyond a rea-
sonable doubt. Along this line, important differences in clini-
cal end points unrelated to IVUS guidance versus angiography 
guidance such as major bleeding emerged (42% relative risk 
reduction in favor of IVUS guidance). Beyond the lack of ran-
domization, there were no prespecified criteria of IVUS-guided 
optimization of stent deployment precluding new knowledge 
of how IVUS could inform the procedure to improve results. 
Similarly, the reader is not informed whether the reading of 
IVUS acquisitions was correct (eg, some physicians participat-
ing had no experience with IVUS according to the authors) and 
whether corrective measures resulted in the anticipated changes, 
because neither the analysis of the pullbacks nor the final angi-
ography were reported. Notwithstanding, IVUS did result in a 
larger stent or balloon diameter in 38%, a longer stent in 22%, or 
higher inflation pressures in 23% of cases, suggesting that IVUS 
might have improved stent underexpansion and malapposition.
What Are the Mechanistic Explanations 
for the Observed Clinical Benefit?
In the context of an observational study design, it is prudent 
to support findings by plausible mechanistic explanations of 
the observed benefits. Clinical end points related to device 
implantation potentially influenced by IVUS guidance were 
only affected, in part, in the present study. Although the data 
do indicate a benefit in terms of target vessel myocardial 
infarction and target lesion revascularization, no difference 
was noted in terms of definite stent thrombosis—the end point 
most likely to be affected by IVUS guidance. A reduction in 
target vessel myocardial infarction unrelated to differences 
in the risk of definite stent thrombosis raises the question of 
alternative explanations and could be potentially explained by 
the progression of de novo coronary artery disease in untreated 
regions of the target vessel. Theoretically, IVUS guidance may 
have improved lesion coverage and reduced geographical miss. 
Consistent with this hypothesis, total stent length was longer in 
the IVUS group, and a reduction in geographical miss has been 
shown to improve outcomes in some analyses.13 A detailed 
review of all coronary angiograms and IVUS sequences of the 
target vessel before and after stent implantation could have sub-
stantiated the presence of vulnerable lesions in the vicinity of 
stented vessel segments owing to incomplete lesion coverage.
Which Patients Are Likely to Benefit 
From IVUS-Guided PCI?
Previous reports observed a benefit from IVUS-guided 
PCI particularly in left main interventions.6 ADAPT DES 
suggests that IVUS guidance may be particularly beneficial 
among patients with complex lesion characteristics including 
left main, bifurcations, and multivessel disease, and among 
patients with acute coronary syndrome, as well, particularly 
those presenting with ST-elevation myocardial infarction 
who are undergoing primary PCI. The latter patients have a 
high risk for recurrent ischemic adverse events,14 which may 
explain why IVUS-guided PCI yielded the largest benefit in 
this subgroup. Optimal selection of stent size and landing 
zone is challenging during primary PCI because of the pres-
ence of thrombus and vessel spasm, and may be facilitated 
by using intracoronary imaging. Whether IVUS, which falls 
short of differentiating thrombus from other tissue types, is 
the ideal imaging technology for the assessment of throm-
botic lesions remains unclear. The importance of adequate 
stent sizing and lumen expansion during PCI has been pre-
viously reported by the same group of investigators in the 
HORIZON-AMI IVUS substudy.15 Contrary to the observa-
tions in ADAPT DES, IVUS guidance during primary PCI 
was not an independent predictor of mortality or definite 
stent thrombosis in the Korea Acute Myocardial Infarction 
Registry including 2127 patients with IVUS guidance and 
8235 control patients.16
In the ADAPT DES registry, all patients with acute coro-
nary syndrome were treated with clopidogrel instead of the 
more potent novel P2Y12 inhibitors ticagrelor and pras-
gurel.17,18 It remains to be shown if and to what degree the 
optimization of stent deployment by intracoronary imaging 
would be camouflaged by the superseding impact of potent 
antithrombotic therapy.
Future Perspectives
It is somewhat disconcerting that after >20 years of intra-
vascular imaging, there remains a void of convincing data 
to support its use in routine clinical practice. Intuitively, any 
imaging technique with superior resolution, improved tissue 
characterization, and easier interpretation should advance 
both diagnosis and treatment. In addition, novel devices such 
as bioresorbable coronary scaffolds require meticulous atten-
tion to lesion characteristics, lesion preparation, and accu-
rate deployment, which may be facilitated by intracoronary 
imaging. Moreover, long-term arterial healing and monitoring 
of the resorption process after scaffold implantation is best 
achieved by intracoronary imaging. The hope remains that 
research in this field and the use of new technologies such 
as optical coherence tomography— a light-based modality 
with 10 times higher resolution than IVUS—will provide con-
vincing outcome data for the more ubiquitous use of intra-
coronary imaging during coronary interventions. Until then, 
 angiography-guided PCI will remain the standard of care that 
may be supplemented by intracoronary imaging in selected 
high-risk patients and a lesions subset such as those deriving 
the greatest benefit in ADAPT DES.
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